ResMed (RMD) sets US $0.60 dividend with Feb 12 record date

Rhea-AI Filing Summary

ResMed Inc. filed a current report describing its latest quarterly results and a new dividend declaration. The company issued a press release covering operations for the quarter ended December 31, 2025, which is furnished as an exhibit and not treated as filed for liability purposes.

ResMed’s board declared a quarterly cash dividend of US $0.60 per share, with a record date of February 12, 2026, payable on March 19, 2026. The dividend will be paid in U.S. dollars to NYSE common stockholders. Holders of CHESS Depositary Instruments on the ASX will receive the equivalent in Australian dollars based on the exchange rate on the record date, reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date is February 11, 2026 for both common stock and CDIs, and ResMed obtained an ASX waiver to defer conversions between its common stock and CDI registers from February 11–12, 2026.

RESMED INC US false 0000943819 0000943819 2026-01-29 2026-01-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Under Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

January 29, 2026

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-15317		98-0152841
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

9001 Spectrum Center Blvd.

San Diego, California 92123

(Address of Principal Executive Offices)

(858) 836-5000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.004 par value		RMD		NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 29, 2026, we issued the press release furnished as Exhibit 99.1. The press release describes the results of our operations for the quarter ended December 31, 2025.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

On January 29, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.60 per share. The dividend will have a record date of February 12, 2026, payable on March 19, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be February 11, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from February 11, 2026, through February 12, 2026, inclusive.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits:		Description of Document
99.1		Press Release dated January 29, 2026, regarding results of operations
104		Cover Page Interactive Data File (embedded within the Inline XBRL, document)

-2-

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: January 29, 2026				ResMed Inc.
				(registrant)
				By:		/s/ Brett Sandercock
				Name:		Brett Sandercock
				Its:		Chief Financial Officer

-3-

FAQ

What did ResMed (RMD) disclose in its latest 8-K filing?

ResMed reported that it furnished a press release describing results for the quarter ended December 31, 2025, and announced a new quarterly cash dividend. The press release is attached as Exhibit 99.1 and is furnished, not filed, for Exchange Act liability purposes.

How much is ResMed’s new quarterly dividend and who will receive it?

ResMed’s board declared a quarterly cash dividend of US $0.60 per share. It will be paid in U.S. dollars to holders of ResMed common stock on the NYSE and in Australian dollars to CDI holders on the ASX, adjusted using the applicable exchange rate.

What are the key dates for ResMed’s US $0.60 dividend?

The dividend has a record date of February 12, 2026 and will be paid on March 19, 2026. The ex-dividend date is February 11, 2026 for both common stockholders on the NYSE and CDI holders on the Australian Securities Exchange.

How are ResMed CHESS Depositary Instruments (CDIs) treated for this dividend?

Holders of ResMed CHESS Depositary Instruments on the ASX will receive an amount in Australian currency equivalent to the US $0.60 per-share dividend. The payment reflects the 10:1 ratio between CDIs and NYSE shares and uses the exchange rate on the record date.

What special ASX waiver did ResMed obtain related to its registers?

ResMed received a waiver from the ASX settlement operating rules allowing it to defer processing conversions between its common stock and CDI registers. This deferral covers the period from February 11, 2026 through February 12, 2026, inclusive, around the ex-dividend and record dates.

Is ResMed’s quarter-end results press release part of this 8-K?

Yes. ResMed’s 8-K states that the press release describing results for the quarter ended December 31, 2025 is furnished as Exhibit 99.1. However, it is expressly noted as furnished, not filed, and is not incorporated into other securities law filings unless specifically referenced.